araag2/HINT huggingface dataset:
Clinical trial NCT00348452 (phase 3, status: completed)
Conditions: chronic pain
ICD codes: G89.29, G89.4, R39.82, G89.22, G89.28, G89.21, G89.3
Drugs: tramadol hcl er; celecoxib
SMILES: COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with American College of Rheumatology (ACR) Functional Class I-III OA of the
             knee or hip;

          -  Patients with involvement of knee or hip joint that warrants treatment with COX-2
             selective inhibitors, NSAIDs, acetaminophen, or opioid analgesics for at least 75 of
             the 90 days preceding the screening visit;

          -  Patients with a pain intensity score in index joint >= 40 mm on the visual analog
             scale(VAS) at the baseline visit;

          -  Patients who are able to discontinue acetaminophen, NSAIDS, COX-2 selective inhibitors
             and other analgesics during the washout period and all analgesics other than the study
             medication throughout the study;

          -  Patients who are able to understand the study procedures and complete the pain scales.

        Exclusion Criteria:

          -  Patients with a medical condition, other than OA, uncontrolled with treatment or any
             clinically significant condition that, in the investigator's opinion, precludes study
             participation or interferes with the assessment of chronic pain and other OA symptoms;

          -  Patients with a diagnoses of inflammatory arthritis, gout, pseudo-gout or Paget's
             disease, that, in the investigator's opinion, interferes with the assessment of pain
             and other symptoms of OA;

          -  Patients with a diagnosis of chronic pain syndrome;

          -  Patients with an ACR or a clinical diagnosis of fibromyalgia;

          -  Patients with any other clinically significant form of joint disease or prior joint
             replacement surgery at the index joint;

          -  Patients with an anticipated need for surgery or other invasive procedure in the index
             joint.
Clinical trial NCT00462540 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: formoterol fumurate inhalation solution 20 mcg, ipratropium bromide 18 mcg and albuterol sulfate 103 mcg
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, [H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N+]2(C)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of COPD

          -  Smoker or exsmoker with at least 10 years smoking at least one pack of cigarettes per
             day

          -  Meet lung function requirements

        Exclusion Criteria:

          -  Diagnosis of Asthma

          -  Significant disease other than COPD

          -  Female pregnant or lactating or planning to become pregnant
Clinical trial NCT00500682 (phase 3, status: completed)
Conditions: chronic kidney disease
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0
Drugs: placebo, ast-120
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [C]
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 years or older

          -  Moderate to severe CKD, not anticipated to require dialysis or renal transplant within
             the next 6 months

          -  Patient survival expected to be no less than one year

          -  Serum creatinine in men >= 2.0 mg/dL (>= 177 µmol/L) and <= 5.0 mg/dL (<= 442 µmol/L),
             and in women >= 1.5 mg/dL (>= 133 µmol/L) and <= 5.0 mg/dL (<= 442 µmol/L) at
             Screening

          -  Urinary total protein to urinary total creatinine ratio must be >= 0.5 on a spot void
             at Screening

          -  Blood pressure <= 160/90 mmHg at both Screening and Baseline. In addition, blood
             pressure, if measured, must have been stable in hypertensive patients over the 3
             months prior to Screening, with no more than 1 blood pressure reading > 160/90 mmHg

          -  In patients being treated for hypertension, they should be on a stable
             anti-hypertensive regimen

        Exclusion Criteria:

          -  Obstructive or reversible cause of kidney disease

          -  Nephrotic syndrome defined as a ratio of urinary total protein to urinary creatinine
             of > 6.0 as measured on a spot void

          -  Adult polycystic kidney disease

          -  History of previous kidney transplant

          -  History of recent (within the past 6 months) accelerated or malignant hypertension

          -  Uncontrolled arrhythmia or severe cardiac disease within the past 6 months

          -  History of malabsorption, inflammatory bowel disease, hiatal hernia, active peptic
             ulcer, or severe GI dysmotility, not attributable to the use of a phosphate binder

          -  Received any investigational agent or participated in a clinical study within the
             previous 3 months

          -  Presence of any significant medical condition that might create an undue risk with
             study participation, or significantly confound the collection of safety and efficacy
             data in this study
Clinical trial NCT00694382 (phase 3, status: completed)
Conditions: venous thromboembolism, cancer
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: semuloparin sodium, placebo (for semuloparin)
SMILES: \N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Cancer patient with metastatic or locally advanced solid tumor of lung, pancreas, stomach,
        colon/rectum, bladder or ovary initiating a (new) course of chemotherapy with a minimum
        intent of 3 months therapy

        Exclusion Criteria:

          -  Required systematic venous thromboprophylaxis or curative treatment with
             anti-coagulant or thrombolytic;

          -  High risk of bleeding;

          -  Severe renal impairment (estimated creatinine clearance <30 mL/min);

          -  ECOG (Eastern Cooperative Oncology Group) performance status 3 & 4;

          -  Major surgery within 4 weeks before randomization;

          -  Known hypersensitivity to unfractionated heparin [UFH] or low molecular weight heparin
             [LMWH].

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial
Clinical trial NCT00708656 (phase 3, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: mesalazine (asacol®)
SMILES: NC1=CC(C(O)=O)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

        Patients who meet the following criteria will be eligible for study entry:

          -  Male and female patients aged over 18 with ulcerative colitis confirmed by histology
             who are in remission (no symptoms of active disease, and modified Baron sigmoidoscopic
             score of 0 or 1)

          -  If female, must be (as documented in patient notes):

               -  postmenopausal (at least 1 year without spontaneous menses), or

               -  surgically sterile (tubal ligation or hysterectomy at least 6 months prior to
                  enrollment), or

               -  using acceptable contraception (e.g., oral, intramuscular, or implanted hormonal
                  contraception) at least 3 months prior to enrollment, or

               -  have a sexual partner with non-reversed vasectomy (with confirmed azoospermia),
                  or

               -  be using 1 barrier method (e.g., condom, diaphragm, spermicide, or intra-uterine
                  device)

          -  Patients whose ulcerative colitis has been in clinical remission for 4 weeks or
             longer, and who have had a symptomatic relapse within the past two years

          -  Patients taking mesalazine, sulfasalazine or other drug containing 5-ASA for 4 weeks
             or longer

          -  Patients capable of giving written informed consent

        Exclusion Criteria:

        The following patients will be excluded from the study:

          -  Patients with Crohn's disease

          -  Patients with symptoms of active colitis

          -  Modified Baron sigmoidoscopy score of 2 or 3

          -  Patients who have used oral, enema, intravenous or suppository preparations of
             corticosteroids, oral or intravenous ciclosporin, mesalazine enemas or suppositories
             within the past four weeks

          -  Patients taking azathioprine or 6-mercaptopurine who have altered the dose or started
             treatment within the past three months, (these drugs permitted in stable dose during
             the study)

          -  Patients with intolerance to Asacol 400 mg or mesalazine

          -  Women who are pregnant or lactating

          -  Patients with known HIV infection

          -  Patients with hepatic disease

          -  Patients with renal impairment (creatinine above local reference range), or with
             positive urine dipstick test to blood or protein

          -  Other serious medical or psychiatric illness that in the opinion of the investigator
             would possibly comprise the study

          -  Patients with problem alcohol excess or drug abuse
Clinical trial NCT00523744 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: amlodipine, olmesartan medoxomil, amlodipine+valsartan, hydrochlorothiazide
SMILES: COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1, CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria for Core study:

          -  Male or female patients (>=18 years)

          -  Females must be either post-menopausal for one year, surgically sterile or using
             effective contraceptive methods

          -  Patients with essential hypertension (diastolic blood pressure >=100 mmHg and <110
             mmHg)

        Inclusion Criteria for Extension:

        - Patients had to have a msSBP >= 140 mmHg and/or msDBP >= 90 mmHg at week 8 ie, end of
        core study.

        Exclusion Criteria for Core study:

          -  Severe hypertension (diastolic blood pressure >=110 mmHg or systolic blood pressure >=
             180 mmHg)

          -  Pregnant or nursing women

          -  Treated hypertensive patients with controlled hypertension under current therapy

          -  A history of cardiovascular disease, including angina pectoris, myocardial infarction,
             coronary artery bypass graft, percutaneous transluminal coronary angioplasty,
             transient ischemic attack, stroke, and heart failure NYHA II - IV

        Exclusion Criteria for Extension:

          -  prematurely discontinued the core study

          -  failed to comply with the core study protocol

        Other protocol-defined inclusion/exclusion criteria applied to the study.
Clinical trial NCT02486354 (phase 3, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: icotinib
SMILES: C#CC1=CC=CC(NC2=NC=NC3=CC4=C(OCCOCCOCCO4)C=C23)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed locally advanced/metastatic (stage
             IIIB/stage IV, using the American Joint Committee on Cancer [AJCC] 6th edition of
             tumor-node-metastasis [TNM] staging system) NSCLC patients

          -  Progressed after at least one platinum-based chemotherapy regimen at entry

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2

          -  At least one measurable lesion by Response Evaluation Criteria in Solid Tumors version
             1.0

          -  Adequate hematologic and biochemical values

        Exclusion Criteria:

          -  Patients with symptomatic brain metastases

          -  Malignant tumor within the previous five years

          -  Severe infection; congestive heart failure

          -  Previous treatment with drugs targeting EGFR

          -  History of interstitial lung disease
Clinical trial NCT00141011 (phase 3, status: terminated)
Conditions: stroke, cerebral ischemia, brain infarction
ICD codes: G46.4, G46.3, Z82.3, P91.821, P91.822
Drugs: ancrod (viprinex), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    futility
  
Eligibility criteria:

        Inclusion Criteria:

          -  Acute, ischemic stroke with first symptoms within 6 hours of beginning treatment

          -  Baseline NIHSS > 5

        Exclusion Criteria:

          -  No intracranial, extravascular blood on CT

          -  Hypertension (systolic > 185; diastolic > 105)

          -  Baseline fibrinogen level < 100 mg/dL

          -  Thrombocytopenia (< 100,000 / mm3)

          -  Recent (< 3 days) or anticipated (< 5 days) use of a thrombolytic agent

          -  Recent (< 14 days) or anticipated surgery
Clinical trial NCT01270347 (phase 3, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: mp-376 (levofloxacin solution for inhalation), tis (tobramycin inhalation solution)
SMILES: C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O
Eligibility criteria:

        Inclusion Criteria (selected):

          -  > 12 years of age

          -  Confirmed Diagnosis of Cystic Fibrosis

          -  Positive sputum culture for P. aeruginosa within the past 12 months

          -  Patients are able to elicit an FEV1 >/= 25% but </= 85% of predicted value at
             screening

          -  Have received at least 3 courses of inhaled tobramycin over the preceding 12 months

          -  Clinically stable with no changes in health status within the last 28 days

          -  Able to reproducibly produce sputum and perform spirometry

        Exclusion Criteria (selected):

          -  Use of any nebulized or systemic antibiotics within 28 days prior to baseline

          -  History of hypersensitivity to fluoroquinolones or inhaled or systemic aminoglycosides
             including tobramycin or any excipients

          -  Evidence of acute upper within 10 days or lower respiratory infections within 28 days
             prior to dosing

          -  CrCl < 20 at Screening

          -  History of lung transplantation

        Extension Portion of the Study: Patients enrolled in Mpex 209 are permitted to participate
        in the open label extension as long as they complete Visit 7 (Day 168), provide informed
        consent for participation in the open label extension of in the study and are clinically
        stable, as assessed by the Investigator.
Clinical trial NCT00316082 (phase 3, status: completed)
Conditions: diabetes
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: saxagliptin, saxagliptin, saxagliptin, saxagliptin, placebo, metformin
SMILES: N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes

          -  Inadequate blood sugar control

        Exclusion Criteria:

          -  Previous treatment for diabetes

          -  Current treatment with other medications to lower blood sugar

          -  Major heart, liver or kidney problems

          -  Women who are pregnant or breastfeeding
Clinical trial NCT00388973 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: quetiapine
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients, 66 years or older, with a documented clinical diagnosis of
             MDD.

        Exclusion Criteria:

          -  The presence of dementia or mental disorder other than MDD within 6 months of
             enrolment,

          -  Uncontrolled hypertension, substance or alcohol abuse

          -  A current diagnosis of cancer or a current or past diagnosis of stroke
Clinical trial NCT00095238 (phase 3, status: completed)
Conditions: congestive heart failure
ICD codes: I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, I50.40
Drugs: irbesartan, placebo
SMILES: CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female age >= 60 years with current symptoms of heart failure consistent with
             New York Heart Association (NYHA) class II-IV

          -  Left ventricular ejection fraction (LVEF) > = 45%

          -  Willing to provide written informed consent AND hospitalization for heart failure
             within the past 6 months OR various abnormalities in electrocardiogram, echocardiogram
             or chest x-ray indicating heart disease.

        Exclusion Criteria:

          -  Acute myocardial infarction within 3 months;

          -  Heart revascularization procedure within 3 months;

          -  Hospitalization for angina within 3 months;

          -  Other heart surgery

          -  Life-threatening or uncontrolled arrhythmia

          -  Subjects with an implantable cardioverter-defibrillator that has discharged in the
             past 3 months;

          -  Stroke or surgery of the arteries in the brain within 3 months;

          -  Serious lung disease which requires use of home oxygen.

          -  Significantly low blood pressure

          -  Significantly high blood pressure

          -  Other known diseases that may limit life expectancy to <3 years;

          -  Known or suspected bilateral kidney artery narrowing;

          -  Geographic or social factors making study participation and follow-up impractical.
Clinical trial NCT01028391 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin 100 mg q.d.+ pioglitazone 45 mg q.d., pioglitazone 45 mg q.d. + sitagliptin 100 mg placebo q.d., metformin
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, N[C@@H](CCCNC(N)=N)C(O)=O, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must complete the double-blind base study (MK-0431-064-00)(NCT00397631) and
             have at least 75% compliance with study medication during the base study treatment
             period.

          -  Women of childbearing potential must continue to comply with the protocol-specified
             contraceptive methods
Clinical trial NCT00120523 (phase 3, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: pimecrolimus, topical corticosteroids
SMILES: [H][C@]1(CC[C@H](Cl)[C@@H](C1)OC)\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC)C(=O)C[C@H](O)[C@H]1C)OC, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Aged 3 to < 12 months

          -  Diagnosis of AD fulfilling the diagnostic criteria of Seymour

          -  AD affecting at least 5% total body surface area

          -  Investigator's Global Assessment (IGA) score of 2 or 3, corresponding to
             mild-to-moderate disease at baseline

          -  Informed consent

        Exclusion Criteria:

          -  Phototherapy, systemic therapy (e.g., immunosuppressants, cytostatics), systemic
             corticosteroids within 4 weeks

          -  Topical tacrolimus or pimecrolimus within 2 weeks

          -  Topical therapy (e.g., tar, topical corticosteroids) within 3 days

          -  Immunocompromised (e.g., lymphoma, AIDS, Wiskott-Aldrich Syndrome) or have a history
             of malignant disease

          -  Active acute viral skin infection (e.g. herpes simplex, herpes zoster, chicken pox),
             and/or clinically infected AD

          -  Failure to thrive (e.g., weight or height/length below the 5th percentile) or
             developmental abnormalities such as head circumference less than 5th and more than
             95th percentile

          -  Known hypersensitivity to any ingredient of pimecrolimus cream 1% or topical
             corticosteroids

          -  Clinical conditions other than AD that according to investigator can interfere with
             the evaluation
Clinical trial NCT00432458 (phase 3, status: completed)
Conditions: multiple myeloma and plasma cell neoplasm
ICD codes: C96.20, C96.29, D47.09
Drugs: thalidomide, zoledronic acid
SMILES: CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2, OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of multiple myeloma (MM)

               -  Previously untreated asymptomatic disease

               -  No requirement for immediate chemotherapy for active MM, such as hypercalcemia
                  from myeloma or painful bone lesions

          -  No solitary plasmacytoma

          -  Measurable or evaluable disease as defined by one of the following:

               -  Serum monoclonal protein ≥ 1.0 g by protein electrophoresis

               -  More than 200 mg of monoclonal protein in the urine by 24-hour electrophoresis

               -  Measurable soft tissue plasmacytoma by physical exam with ruler or by MRI or
                  positron emission tomography/CT scan

                    -  If the only measurable lesion is the plasmacytoma, it must be ≥ 1.5 cm in 1
                       dimension

          -  Must have ≥ 10% plasma cells as measured on the bone marrow aspirate, bone marrow
             biopsy, or labeling index

          -  No amyloidosis

        PATIENT CHARACTERISTICS:

          -  Performance status 0-2

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 8.0 g/dL

          -  Creatinine ≤ 2.0 mg/dL (elevation above normal range should not be felt to be related
             to myeloma)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use 2 methods of effective contraception 4 weeks before, during,
             and for 4 weeks after completion of study treatment

          -  No uncontrolled infection

          -  No other active malignancy

          -  No New York Heart Association class III or IV heart disease

          -  No pre-existing neuropathy ≥ grade 2

          -  No concurrent major dental work

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Prior corticosteroids (for nonmalignant disorders) allowed

          -  Prior therapy with experimental agents not shown to have significant activity in MM,
             such as clarithromycin, dehydroepiandrosterone, and anakinra allowed

          -  No prior thalidomide or corticosteroids for MM

          -  No more than 3 doses of IV zoledronate or pamidronate within the past 12 months

          -  At least 3 months since prior radiotherapy, including radiotherapy for solitary
             plasmacytoma

          -  No concurrent oral bisphosphonate therapy for osteoporosis